1. |
- Fenaux, P, et al.
(författare)
-
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- 2011
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 118:14, s. 3765-3776
-
Tidskriftsartikel (refereegranskat)abstract
- This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed after 16 weeks. More patients in the lenalidomide 10- and 5-mg groups achieved RBC-transfusion independence (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was not reached (median follow-up, 1.55 years), with 60% to 67% of responses ongoing in patients without progression to acute myeloid leukemia (AML). Cytogenetic response rates were 50.0% (10 mg) versus 25.0% (5 mg; P = .066). For the lenalidomide groups combined, 3-year overall survival and AML risk were 56.5% and 25.1%, respectively. RBC-TI for ≥ 8 weeks was associated with 47% and 42% reductions in the relative risks of death and AML progression or death, respectively (P = .021 and .048). The safety profile was consistent with previous reports. Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome. This trial was registered at www.clinicaltrials.gov as #NCT00179621.
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
- Fenning, D. P., et al.
(författare)
-
Iron distribution in silicon after solar cell processing: Synchrotron analysis and predictive modelling
- 2011
-
Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 98, s. 162103-
-
Tidskriftsartikel (refereegranskat)abstract
- The evolution during silicon solar cell processing of performance-limiting iron impurities isinvestigated with synchrotron-based x-ray fluorescence microscopy. We find that during industrialphosphorus diffusion, bulk precipitate dissolution is incomplete in wafers with high metal content,specifically ingot border material. Postdiffusion low-temperature annealing is not found to alterappreciably the size or spatial distribution of FeSi2precipitates, although cell efficiency improvesdue to a decrease in iron interstitial concentration. Gettering simulations successfully modelexperiment results and suggest the efficacy of high- and low-temperature processing to reduce bothprecipitated and interstitial iron concentrations, respectively.
|
|